Novavax (NVAX) PT Raised to $2.50
Novavax (NASDAQ:NVAX) had its price target upped by equities research analysts at Piper Jaffray Companies to $2.50 in a report released on Thursday. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target would indicate a potential upside of 16.82% from the company’s current price.
Other research analysts also recently issued reports about the company. S&P Equity Research dropped their price target on Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. B. Riley set a $2.25 price target on Novavax and gave the stock a “buy” rating in a research note on Friday, January 5th. BidaskClub raised Novavax from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. Ladenburg Thalmann Financial Services increased their price objective on Novavax to $2.50 and gave the stock a “buy” rating in a research note on Thursday, January 11th. Finally, Citigroup reissued a “hold” rating and issued a $3.00 price objective on shares of Novavax in a research note on Tuesday, February 20th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Novavax currently has a consensus rating of “Hold” and an average price target of $3.11.
Novavax (NASDAQ:NVAX) opened at $2.14 on Thursday. Novavax has a 52 week low of $0.73 and a 52 week high of $2.75. The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31. The firm has a market capitalization of $671.14, a P/E ratio of -3.15 and a beta of 2.49.
ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/novavax-nvax-pt-raised-to-2-50/1903915.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.